147 related articles for article (PubMed ID: 32515802)
21. Oxytocin as a potential defence against Covid-19?
Soumier A; Sirigu A
Med Hypotheses; 2020 Jul; 140():109785. PubMed ID: 32344303
[No Abstract] [Full Text] [Related]
22. Imatinib is not a potent anti-SARS-CoV-2 drug.
Zhao H; Mendenhall M; Deininger MW
Leukemia; 2020 Nov; 34(11):3085-3087. PubMed ID: 32999432
[No Abstract] [Full Text] [Related]
23. Pharmacologic Therapy for COVID-19 Infection.
Nusbaum N
J Community Health; 2020 Jun; 45(3):435-436. PubMed ID: 32314081
[TBL] [Abstract][Full Text] [Related]
24. Tackling SARS-CoV-2: proposed targets and repurposed drugs.
Joshi S; Joshi M; Degani MS
Future Med Chem; 2020 Sep; 12(17):1579-1601. PubMed ID: 32564623
[TBL] [Abstract][Full Text] [Related]
25. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.
Parvez MSA; Karim MA; Hasan M; Jaman J; Karim Z; Tahsin T; Hasan MN; Hosen MJ
Int J Biol Macromol; 2020 Nov; 163():1787-1797. PubMed ID: 32950529
[TBL] [Abstract][Full Text] [Related]
26. Repurposing antimalarials and other drugs for COVID-19.
Schlagenhauf P; Grobusch MP; Maier JD; Gautret P
Travel Med Infect Dis; 2020; 34():101658. PubMed ID: 32247925
[No Abstract] [Full Text] [Related]
27. The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro.
Okamoto M; Toyama M; Baba M
Antiviral Res; 2020 Oct; 182():104902. PubMed ID: 32739404
[TBL] [Abstract][Full Text] [Related]
28. Puzzle of highly pathogenic human coronaviruses (2019-nCoV).
Li J; Liu W
Protein Cell; 2020 Apr; 11(4):235-238. PubMed ID: 32088858
[No Abstract] [Full Text] [Related]
29. Bioactive compounds with possible inhibitory activity of Angiotensin-Converting Enzyme-II; a gate to manage and prevent COVID-19.
Dabaghian F; Khanavi M; Zarshenas MM
Med Hypotheses; 2020 Oct; 143():109841. PubMed ID: 32425303
[No Abstract] [Full Text] [Related]
30. Chloroquine and its derivatives in the management of COVID-19: A scoping review.
Pimentel J; Andersson N
Biomedica; 2020 Oct; 40(Supl. 2):80-95. PubMed ID: 33152192
[TBL] [Abstract][Full Text] [Related]
31. COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?
Alany RG
Pharm Dev Technol; 2020 Jul; 25(6):649. PubMed ID: 32423342
[No Abstract] [Full Text] [Related]
32. Mass Drug Administration and Worms Experience in Africa: Envisage Repurposing Ivermectin for SARS-COV-2.
Wamae CN
Am J Trop Med Hyg; 2020 Jul; 103(1):10-11. PubMed ID: 32458795
[No Abstract] [Full Text] [Related]
33. Cationic drugs and COVID-19.
Brenna OV; Torretta S; Pignataro L; Di Berardino F
Int J Immunopathol Pharmacol; 2020; 34():2058738420966078. PubMed ID: 33045858
[TBL] [Abstract][Full Text] [Related]
34. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
35. Old Drugs for a New Virus: Repurposed Approaches for Combating COVID-19.
Saul S; Einav S
ACS Infect Dis; 2020 Sep; 6(9):2304-2318. PubMed ID: 32687696
[TBL] [Abstract][Full Text] [Related]
36. Weak Induction of Interferon Expression by Severe Acute Respiratory Syndrome Coronavirus 2 Supports Clinical Trials of Interferon-λ to Treat Early Coronavirus Disease 2019.
O'Brien TR; Thomas DL; Jackson SS; Prokunina-Olsson L; Donnelly RP; Hartmann R
Clin Infect Dis; 2020 Sep; 71(6):1410-1412. PubMed ID: 32301957
[No Abstract] [Full Text] [Related]
37. Databases for the targeted COVID-19 therapeutics.
Wang Y; Li F; Zhang Y; Zhou Y; Tan Y; Chen Y; Zhu F
Br J Pharmacol; 2020 Nov; 177(21):4999-5001. PubMed ID: 32845521
[No Abstract] [Full Text] [Related]
38. Discovering drugs to treat coronavirus disease 2019 (COVID-19).
Dong L; Hu S; Gao J
Drug Discov Ther; 2020; 14(1):58-60. PubMed ID: 32147628
[TBL] [Abstract][Full Text] [Related]
39. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
Pneumologie; 2020 Sep; 74(9):611-614. PubMed ID: 32916743
[No Abstract] [Full Text] [Related]
40. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
Choudhary S; Malik YS; Tomar S
Front Immunol; 2020; 11():1664. PubMed ID: 32754161
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]